<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5713">
  <stage>Registered</stage>
  <submitdate>22/12/2014</submitdate>
  <approvaldate>22/12/2014</approvaldate>
  <nctid>NCT02326233</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects</studytitle>
    <scientifictitle>A Randomised, Open-labelled, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of the Pre-filled Pen and PFS of SB5 in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-005178-12</secondaryid>
    <secondaryid>SB5-G12-NHV</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Pen of SB5
Other interventions - PFS of SB5

Experimental: Pen of SB5 - Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)

Active Comparator: PFS of SB5 - PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)


Other interventions: Pen of SB5


Other interventions: PFS of SB5


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under the concentration-time curve from time zero to infinity (AUCinf)</outcome>
      <timepoint>57 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)</outcome>
      <timepoint>57 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum serum concentration (Cmax)</outcome>
      <timepoint>57 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to reach Cmax (Tmax)</outcome>
      <timepoint>57 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy subjects

          -  Have a body mass index between 20.0 to 29.9 kg/mÂ², inclusive.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History and/or current presence of clinical significant atopic allergy,
             hypersensitivity or allergic reactions, also including known or suspected clinically
             relevant drug hypersensitivity to any components of the test and reference
             investigational product formulation or comparable drugs

          -  Active or latent Tuberculosis or who have a history of Tuberculosis

          -  History of invasive systemic fungal infections or other opportunistic infections

          -  Systemic or local infection, a known risk for developing sepsis and/or known active
             inflammatory process

          -  Serious infection associated with hospitalisation and/or which required intravenous
             antibiotics

          -  History of and/or current cardiac disease

          -  Have received live vaccine(s) within 4 weeks prior to Screening or who will require
             live vaccine(s) between Screening and the subject's last visit

          -  Intake medication with a half-life &gt; 24 h within 4 weeks or 10 half-lives of the
             medication prior to investigational product administration</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>190</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Samsung Bioepis Co., Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of the
      pre-filled pen and pre-filled syringe of SB5 in healthy subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02326233</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>